PNC Financial Services Group Inc. Purchases 20,422 Shares of Moderna, Inc. $MRNA

Posted by Stanley Muller on Jul 29th, 2026

PNC Financial Services Group Inc. raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 41.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 69,883 shares of the company’s stock after buying an additional 20,422 shares during the period. PNC Financial Services Group Inc.’s holdings in Moderna were worth $3,550,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Capital World Investors acquired a new position in Moderna during the fourth quarter worth $378,299,000. Alyeska Investment Group L.P. acquired a new position in shares of Moderna in the fourth quarter valued at about $95,209,000. Norges Bank acquired a new stake in Moderna during the fourth quarter worth approximately $79,707,000. Invesco Ltd. grew its stake in Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after buying an additional 1,115,131 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Moderna by 123.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock worth $52,775,000 after purchasing an additional 987,312 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on MRNA shares. Morgan Stanley increased their price objective on shares of Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 8th. Royal Bank Of Canada lifted their price objective on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Wolfe Research reissued an “underperform” rating and issued a $25.00 price objective on shares of Moderna in a research note on Monday, July 20th. Bank of America upped their target price on shares of Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Reduce” and an average price target of $40.00.

Read Our Latest Report on MRNA

Moderna Stock Performance

Moderna stock opened at $55.81 on Wednesday. The stock has a market cap of $22.14 billion, a P/E ratio of -6.85 and a beta of 0.94. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $85.60. The firm’s fifty day moving average price is $58.87 and its 200-day moving average price is $52.19.

Moderna (NASDAQ:MRNA – Get Free Report) last released its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same period in the prior year, the business posted ($2.52) EPS. Moderna’s revenue for the quarter was up 260.2% on a year-over-year basis. On average, equities research analysts expect that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Insider Activity

In other Moderna news, Director Abbas Hussain sold 5,682 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director owned 12,066 shares in the company, valued at approximately $562,637.58. The trade was a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 125,088 shares of company stock worth $6,193,713. 10.80% of the stock is currently owned by corporate insiders.

Moderna Company Profile

(Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.